13 YEAR OLD BOY WHO SURVIVED RARE CHILDHOOD CANCER TWICE SUPPORTS NEW FUNDRAISING CAMPAIGN – MENAFN.COM

(MENAFN - Pressat) 13 year old Ryan Savage, from Billingham in Stockton-on-Tees, features in a new Christmas campaign with Neuroblastoma UK, to raise vital funds for neuroblastoma research.

Ryan was first diagnosed with neuroblastoma, a rare childhood cancer, when he was just three years old. He was given a 5% chance of survival and doctors told his parents that he may not live to see Christmas.

This Christmas campaign aims to #GiveHope to families like Ryan's, by raising money for leading research projects which aim to deliver new, more effective and kinder treatments for children with neuroblastoma.

Ryan's mum Lisa says, 'Christmas is Ryan's favourite time of year - he's not a child who asks for much but he is always just so happy to celebrate Christmas with his family. Every time Christmas comes around, it's a precious reminder to our family that another year has passed since Ryan fought this terrible disease twice, and won.

'Ryan was first diagnosed with neuroblastoma on 29th October 2009 - a date that will be etched on my memory forever. He came home from nursery complaining of stomach pains. He wouldn't eat and the pain got worse, so I took him to A&E that night. Doctors thought it was constipation or trapped wind but two days later, he had a high temperature, was in extreme pain and, worryingly, he couldn't move his legs.

'We took him back to A&E and they did an immediate MRI scan. They found a tumour wrapped around Ryan's spine and we were told that Ryan could have less than two months to live, and he might not see Christmas.

Our world was turned upside-down by a cancer we had never even heard of before.'

Ryan began chemotherapy immediately, followed by surgery to remove the majority of his tumours. After a gruelling year of cancer treatment, Ryan was in remission and the family could celebrate another Christmas together.

But two years later, doctors found another tumour in his chest and their consultant said it was the worst case that she'd ever seen.

'Our little man endured another two really tough years of treatment including chemotherapy, radiotherapy, a stem cell transplant and major surgery. He also needed ribs removed as the cancerous tumours had wrapped around his little bones. By March 2012, the only tumour left in his body was a growth behind his heart. In October 2013, the heart tumour no longer appeared on his scans.

Ryan endured years of treatment including chemotherapy, radiotherapy, a stem cell transplant and major surgery, after having neuroblastoma twice.

'Seeing what Ryan went through, it breaks my heart to think of all those children fighting neuroblastoma this Christmas. They should be at home enjoying the fun of the festive season with their families. I know from personal experience that their parents will be hoping against hope that the treatment their children receive will help them beat neuroblastoma too.

'Little children simply don't deserve to be robbed of their precious early years, nor should they have the threat of their cancer returning constantly hanging over them. But there is still so much more research that needs to be done to prevent children suffering like Ryan did.'

Katherine Mobey, Fundraising Manager at Neuroblastoma UK said, 'Neuroblastoma is a cancer that almost exclusively affects children, with around 100 children diagnosed every year in the UK. Christmas is a time when families should be together and having fun, not going through harsh cancer treatment.

'With our new fundraising campaign, we want to give hope to more families like Ryan's. By funding more vital research, we can help scientists search for new and kinder treatments, give children with neuroblastoma a better quality of life after treatment, and move closer to finding a cure.'

To make a donation, visitwww.neuroblastoma.org.uk/christmas .

MENAFN30112019007010603ID1099348289

The rest is here:
13 YEAR OLD BOY WHO SURVIVED RARE CHILDHOOD CANCER TWICE SUPPORTS NEW FUNDRAISING CAMPAIGN - MENAFN.COM

Heartbreaking photograph shows the reality of childhood cancer – Yahoo News

Sophia Soto is pictured tearfully awaiting cancer treatment. [Photo: Caters]

The mother of a cancer survivor has released a heartbreaking photograph to show the reality of the disease.

Sophia Soto, from Florida, was diagnosed with stage four neuroblastoma at just 14 months old after unusual bruises developed around her eyes.

READ MORE:Girl with neuroblastoma declared cancer-free after pioneering treatment

With doctors dismissing it as just a fall, an eye specialist eventually found tumours behind her eyes were to blame.

The toddler endured 60 rounds of chemo, 20 of radiotherapy and a stem cell transplant over six months. She was snapped just before having treatment.

Sophia, now six, has been in remission for five years and medication-free for the past 24 months.

Speaking of her daughters condition, Sophias mother Rosie Soto, 40, said: The picture of Sophia upset really does hone in on the reality of childhood cancer.

She was having a lead put on her chest for her treatment, which she didn't want, hence why Sophia was so upset.

I look back at the picture now and wonder how I did it. It was so hard watching my little girl so ill.

Neuroblastoma is a rare type of cancer that mainly affects babies and young children,according to the NHS.

READ MORE:Childhood Cancer Survivors Are Twice as Likely to Have This Condition

Around 95 youngsters in the UK are diagnosed every year, making up 6% of all childhood-cancer cases,Children with Cancer UK statistics show.

In the US, around 800 are diagnosed annually, also accounting for 6% of all cases,according to the American Cancer Society.

Neuroblastoma develops in specialised nerve cells called neuroblasts, which get left behind during a babys development in the womb.

The disease tends to start in one of the adrenal glands above the kidneys or nerve tissue next to the spinal cord, before spreading.

Mrs Soto became concerned when her daughter develop bruises around her eyes, with no obvious cause.

I kept taking her to the doctors because the bruising wasn't going away, but they just said it must have been from a bump or something, she said.

Sophia wasn't referred for a scan or biopsy until I went to an eye specialist, who knew straight away it was caused by a tumour.

Story continues

She was sent for an MRI, where black spots appeared on the scans confirmed the tumours behind her eyes.

[A] biopsy found tumours on one of her kidneys as well, which led to her stage four neuroblastoma diagnosis.

Sophia discovered she had the disease in March 2014, aged just 14 months.

After extensive treatment, the youngster has been in remission since that November, but still has check-ups every six months.

The tumours behind her eyes cannot be removed, however, doctors believe they are now benign.

READ MORE: Mom beats breast cancer and then books 'dream' trip

Doctors are reluctant to remove the tumours Sophia has behind her eyes as they've said it would be likely the surgery [would] disfigure her face, Mrs Soto said.

Whilst they are tumours, doctors are reasonably confident they are not cancerous so we have decided to not have the surgery right now, but it may be something she has when she's older.

Over the worst, Sophia loves dancing and dreams of one day becoming a vet.

No one can imagine what she went through looking at her now, she just looks like a normal regular child, Mrs Soto said.

Sophia has her moments when she asks about when she was sick and has questions about her treatment scars, but overall she's a pretty happy girl.

If I was to say anything to other parents with children battling cancer, I'd say to not give up, stay positive.

It's really important not to compare your child's process to anyone else as everyone battles illnesses differently.

We're over the moon Sophia is now doing so well. We're really blessed she's such a fighter.

Follow this link:
Heartbreaking photograph shows the reality of childhood cancer - Yahoo News

"For the first time in 25 years this means hope" – Leeds family fundraising for life-changing MS treatment – Yorkshire Post

A Leeds family are desperately raising funds to help pay for a "life-changing" treatment that could halt the progression of Multiple Sclerosis.

Father-of-two Jean-Christophe Verro, 47, lives with MS - a condition that affects the brain and spinal cord.

There is no cure for MS and symptoms, which include vision problems, speech and swallowing difficulties and mobility problems, can develop and worsen steadily over time.

Mr Verro, a former captain in the French Marines, was diagnosed with the condition in 1995 and following a relapse in 2015, he now uses a wheelchair.

He and his wife Lisa Verro, who live Moortown, now want to raise 55,000 for private Hematopoietic Stem Cell Therapy to try and stop symptoms progressing.

Explaining the illness, Mrs Verro, 45, said: "MS itself is not fatal - it is the side effects that go through your facilities one by one.

"He could lose his brain function, start having seizures, become bedridden or have trouble with swallowing.

"It's very unpredictable. There's no cure, no drug treatment.

"We can deal with it as it is now but if he starts to lose his functions it will be so difficult. His main concern is the brain shrinkage and I worry that if he loses his functions, say in his arms, he wont be able to drive or go out into the local community.

"This would devastate him as he is very independent and works full time.

She added: "When came out of hospital in 2015 the doctors said "why don't you give up work" but that's just not my husband.

"He tries to just get on with it. He tries to live as normally as possible. He likes his job and contributing to society, he doesn't want to be on benefits.

"He just wants to be like and do what every other dad does."

Mr and Mrs Vero, who are parents to seven-year-old Oliver and five-year-old Charlotte, first became aware of the HSCT treatment during a BBC Panaroma programme.

Since then they have come across various groups on Facebook with people who have successfully had the treatment.

According to the Multiple Sclerosis Trust, the number of people who are accepted for treatment on the NHS is extremely small.

Mr Verro did not meet the criteria for the limited NHS treatment and now the family are hoping to have the treatment abroad in May.

Mrs Verro said: "If he doesn't have it in May it could never happen. His condition is unpredictable so he could not be well enough.

"This treatment would be life-changing for us as a family.

"My son's bedroom is in the attic and he's always saying, 'I want my daddy to be able to play Lego with me in my bedroom or 'I just want to play football in the park with my daddy' but it isn't possible.

"The kids don't appreciate the seriousness of his condition and how it can progress - that's what we are thinking about with this treatment.

"We have two young children, we've got to try whatever we can to stop the progression.

"We appreciate that its a very large some of money to give but I hope the the local community can get behind us."

For Mr Verro, even the possibility of receiving the treatment has given him "hope" for the future.

The SEO manager said: "For the first time in 25 years this means hope.

"Since being diagnosed with MS in 1995, I have been through every step - there's no way out of it. No treatments, no cure.

"I've tried most treatments and they come with a lot of serious side effects.

"Apparently some clinics have been offering this treatment for 20 years. I just wish I had known about it three or five years ago.

"It just feels like hope after so long - like the windows and the shutters have been closed and now here is the chance to open them out wide and take a big deep breath of fresh air."

The family have already raised 3,000 of their target.

They have opened a Go Fund Me page and will be hosting a series of events in the community.

A Reindeer Dash has been organised in Roundhay Park involving a 5k or 2k run/walk, as well as a raffle.

it costs 15 per adult and 8 per child and guests will receive reindeer antlers, flashing red nose and mince pies in the entry fee,

It will take place on Saturday, December 14 at 10am.

Jean-Christophe's fundraising page can be found here.

See more here:
"For the first time in 25 years this means hope" - Leeds family fundraising for life-changing MS treatment - Yorkshire Post

Family releases photo sharing the reality of childhood cancer – NEWS.com.au

A family have released the heartbreaking photograph of their toddler undergoing cancer treatment to highlight the reality of childhood cancer.

Sophia Soto, now six, from America, was diagnosed with stage 4 neuroblastoma an aggressive and rare cancer at just 14 months old after tumours were discovered behind her eyes and on her kidney.

The heartwrenching photograph is of Sophia having a lead put on her chest as part of her cancer treatment.

But luckily little Sophia has been in remission for five years and now looks like a completely different child compared to the one in the heart wrenching photograph.

The picture of Sophia upset really does home in on the reality of childhood cancer, her mum Rosie Soto, 40, said.

She was having a lead put on her chest for her treatment which she didnt want hence why Sophia was so upset.

I look back at the picture now and wonder how I did it; it was so hard watching my little girl so ill.

Rosie became concerned about Sophia after she began developing bruising around her eyes something she claims doctors repeatedly dismissed as being from a bump or fall.

It wasnt until Rosie took Sophia to see an eye specialist that she got some answers.

Sophia kept getting bruising on her eyes and I didnt recall her falling over or anything, so I didnt understand where they were come from, Rosie said.

I kept taking her to the doctors because the bruising wasnt going away, but they just said it must have been from a bump or something.

Sophia wasnt referred for a scan or biopsy until I went to see an eye specialist with her who knew straight away that it was caused by a tumour.

She was sent for an MRI where black spots appeared on the scans confirming the tumours behind her eyes.

It was then the biopsy which found the tumours on one of her kidneys as well which led to her stage 4 neuroblastoma diagnosis.

After being diagnosed in March 2014, the then 14-month-old endured 60 rounds of chemotherapy, 20 rounds of radiation and a stem cell transplant over a six months period.

Following her treatment, Sophia has been in remission since November 2014 and has been medication free for two years.

Sophia isnt yet classified as cancer free so has check ups every six months with specialists.

She still has tumours behind her eyes which cannot be removed due to the placement of them, but doctors believe the tumours are benign and therefore not causing her too much harm.

Doctors are reluctant to remove the tumours Sophia currently has behind her eyes as theyve said it would be likely the surgery to disfigure her face, Rosie said.

Whilst they are tumours, doctors are reasonably confident that they are not cancerous so we have decided to not have the surgery right now, but it may be something she has when shes older.

Sophia now looks happy and healthy. She loves to dance and hopes to become a vet one day.

No one can imagine what she went through looking at her now she just looks like a normal regular child, Rosie said.

Sophia has her moments when she asks about when she was sick and has questions about her treatment scars, but over all shes a pretty happy girl.

If I was to say anything to other parents with children battling cancer, Id say to them to not give up, stay positive and keep your faith.

Its really important not to compare your childs process to anyone else as everyone battles illnesses differently as every situation is different.

Were over the moon that Sophia is now doing so well were really blessed that shes such a fighter.

Read more from the original source:
Family releases photo sharing the reality of childhood cancer - NEWS.com.au

Calgary MP won’t give up effort to add donor consent option to tax forms – Calgary Herald

Calgary MP Len Webber has become a dogged advocate for increasing Canada's rate of organ and tissue donation.Crystal Schick / Postmedia

Its a crusade that began with his beloved wifes dying regret.

Calgary MP Len Webber has become a dogged advocate for increasing Canadas rate of organ and tissue donation, a fire that was kindled after his wife lost a lengthy battle with breast cancer in 2010.

When she did pass away, she said the one regret she had was that she wasnt able to donate her organs, said Webber, who in October was elected to his second term in the House of Commons after serving for a decade as a Calgary MLA.

From there, it just evolved. You start getting involved and the more you do that, the more you get motivated to do what you can.

Three years after her death, Webbers private members bill, the Human Tissue and Organ Donation Amendment Act, was passed by the Alberta legislature, establishing a single agency to co-ordinate organ and tissue donations while also establishing a provincial organ donor registry. It further required agents at provincial registry offices to ask for peoples consent to become an organ or tissue donor.

But Webber wasnt finished.

Soon after he was elected to represent the federal riding of Calgary Confederation, Webber started working on a plan to bring the conversation of organ and tissue donation to every Canadian household.

So, he turned to one of lifes two certainties as a new lever to increase the nations donor corps taxes.

Last November, Webber received unanimous consent on Bill C-316, a private members bill that will add a question on tax forms about whether people will consent to becoming organ and tissue donors. Those who sign up will then be added to the rolls of provincially run organ donor registries.

This is not a political issue; it is a human issue, he said last September in the House of Commons.

Any one of us could be in need of donor organs or tissues at any time. Just asking this simple question could increase the number of donors.

Canada remains a middling performer globally when it comes to organ and tissue donation, with about 22 Canadians per million population becoming donors. Despite consistent polling that finds about nine in 10 Canadians in support of the idea of donating their organs, only around 20 per cent nationwide have their names on donor registries, a puzzling ratio Webber has long hoped to narrow.

Webber dedicated the bill to his friend Robert Sallows of Red Deer who received a double lung transplant when he was just 17, and had become an ardent supporter and counsellor to the Calgary MP as he crafted the proposed legislation, even through deteriorating health.

He helped me lobby that bill even through his difficult time, said Webber, noting Sallows also helped him pass the bill that created Albertas organ donor registry.

Sallows died just a week before the federal legislation, which he helped craft, passed second reading unanimously in a rare show of support across party lines.

It went on to the Canadian Senate but died on the order paper when the federal election was called in September, meaning Webber will now have to start the process anew.

I lobbied hard in the Senate to get this through, but the Senate is also very political, he said. It died on the table. So, now I have to bring it back to the House of Commons.

Despite his disappointment, Webber expects the bill will now face a smoother ride among his parliamentary colleagues, though he admits the uncertainty of how it might be impacted by a minority government is troubling.

I do worry about minority governments because not a lot happens, he said. However, a bill like this shouldnt be political. Its something all parties agree with so damn it, lets get it done.

This concludes a month-long project from Postmedia Calgary and Edmonton, which examines the state of organ donation in Alberta whats working, what isnt and how the system can be improved. Catch up on the series here:

Also, Albertans share how the issue of organ transplants has changed their lives:

See the article here:
Calgary MP won't give up effort to add donor consent option to tax forms - Calgary Herald

World AIDS Day 2019: 37.9M people worldwide were living with HIV at the end of 2018 – USA TODAY

Autoplay

Show Thumbnails

Show Captions

People around the world on Sunday observed the 31stannual World AIDS Day, an eventfirst declared in 1981 aimed atraising awareness of the HIV/AIDS epidemic. It was first declared by the World Health Organization.

According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), 37.9 million people around the world were living with HIV at the end of 2018. UNAIDS reports 1.7 million people worldwide were newly infected in 2018.

The CDC reports 1.1 million people were living with HIV in the United States at the end of 2016 and one in seven people nationwide who had the disease didnt know they were infected.

37,832 people received an HIV diagnosis in the United States and dependent areas, according to the CDC.

Worldwide, 770,000 people died from AIDS-related illnesses in 2018, according to UNAIDS. The CDC reports there were 16,350 deaths among people diagnosed with HIV in the United States. The agency added the deaths may be due to any cause.

An activist paints his hand with AIDS awareness message during a campaign on the eve of World AIDS Day in Kolkata, Eastern India.(Photo: PIYAL ADHIKARY/EPA-EFE)

HIV stands forhuman immunodeficiency virus. AIDS stands for acquired immunodeficiency syndrome.

HIV is a virus that can lead to AIDS.AIDS is the lastof thethree stages of HIV infection.

According to the Centers for Disease Control and Prevention, people in the first stage, acute HIV infection, experience a flu-like illness within 2 to 4 weeks after infection.Itcan last a few weeks. People in this stagehavelarge amounts of the virus in their blood,and so are more likely to transmit the infection.

The second stage, clinical latency, marks a period where the virus is active but reproduces only at low levels, HIV.gov says. People in this stagemight not experience symptoms, but can still transmit HIV to others. This stage can last decades, depending on treatment, but can also be shorter.

AIDS, the third stage,leads to the mostsevere illnessesbecause the virus damages the immune system over time, the CDC says. On average, people with AIDS who don't get treatment survive three years, according to the CDC.

Treatment at all three stagescan prevent or slow symptoms and reduce the risk of transmission, the CDC says.

Testing is the best way to determine whether you have HIV, but symptoms can occur beforeHIV shows up on a test. Some experience flu-like symptomsincludingfever, chills, rash, night sweats, muscle aches, sore throat, fatigue, swollen lymph nodesor mouth ulcerswithin two weeks of infection.

HIV attacks your immune system by reducing CD4 cells, or T cells, makingit harder to fight other infections."Over time, HIV can destroy so many of these cells that the body cant fight off infections and disease," according to HIV.gov.

According to HIV.gov, the condition becomesAIDS whenT cellcounts drop below200 cells per cubic millimeter of blood,or certain AIDS-related complications suchassevere infectionsappear.

Students carry a red ribbon during world Aids day campaign in Dharamsala, India on December 1, 2019. World AIDS Day is observed every December 1 with calls from international health and advocacy organizations for the public to get involved in programs for awareness, prevention and treatment of human immunodeficiency virus infection and acquired immune deficiency syndrome. (Photo: Sanjay Baid, EPA-EFE)

A person can become infected with HIV only through certain activities in which they come intocontact with certain bodily fluids.

Blood, semen, pre-seminal fluid, rectal fluids, vaginal fluidsand breast milk can transmit HIV, according to the CDC.

"These fluids must come in contact with a mucous membrane or damaged tissue or be directly injected into the bloodstream (from a needle or syringe) for transmission to occur," the CDC says.

Unprotected anal or vaginal sex with someone who has HIV is one of two main ways the virus is spread in the United States, according to HIV.gov. Use of a contaminated needle or syringe is the other.

A mother may pass the virus on to her child duringpregnancy, birthor breastfeeding. It can also be contracted bybeing struck by an item contaminated with HIV. Other rare but possible ways to spread HIV can be found here.

The Chain Bridge is illuminated in red to mark World AIDS Day in Budapest, Hungary on December 1, 2019.(Photo: Marton Monus, EPA-EFE)

U.S. scientists found the first clinical evidence for the disease that would become known as AIDS in 1981, according to the United Nations. Chimpanzees in Central Africa have been identified as the source of HIV in humans. Their version of the virus, calledSIV,was likely transmitted to humans and then mutated, the CDC says. HIV has existed in the United States since the mid- to late 1970s.

Yes. People with HIV can take a series of drugs, called antiretroviral therapy, or ART,that slows the virus from progressing, keeps them healthy for years and drastically reduces their likelihood of spreading the virus, the CDC says.

epaselect epa08037135 A 3D printed statue of the Dutch AIDS foundation is unveiled in the center of Amsterdam, the Netherlands, 01 December 2019. The image sheds a tear every 40 seconds and was unveiled on the occasion of World AIDS Day. EPA-EFE/ROBIN VAN LONKHUIJSEN ORG XMIT: 402553629(Photo: ROBIN VAN LONKHUIJSEN, EPA-EFE)

Not yet. Researchers are working toward a cure. Ifa cure were to be found, it'd likely take one of two forms, according tothe National Institute of Allergy and Infectious Diseases.

Viral eradication would mean HIV was eliminated from a patient's body. The approachwould involve "prodding the virus out of its latent state so that an enhanced immune system or administered therapies can target and eliminate HIV-infected cells," the NIAID says. Researchers are also studying gene mutations in certain people whose immune cells resist HIV.

A functional cure, or sustained ART-free remission, would mean that HIV wasnot eliminated, but rather suppressed to a point at which daily medication would no longer be longer required.

No, but there have been a number of developments. The National Institutes of Health opened the first clinical trial with138 healthy, HIV-negative volunteers in 1987, according tothe National Institute of Allergy and Infectious Diseases.

In 2016,the NIH announced avaccine-efficacy trial in South Africa of 5,400 people, the largest in the country's history. Researchers are building on a 2009 success in Thailand, where for the first time ever a vaccine showed modest success in preventing HIV infections.

Princy Mangaika, executive director of Positive Women's Network (PWN), herself an HIV-infected patient, makes AIDS awareness ribbons at her residence in Colombo, Sri Lanka, on Sunday.(Photo: Chamila Karunarathne, EPA-EFE)

The CDC recommends everyone from ages 13 to 64 get tested at least once.

People at greater risk of infection, such as sexually active gay or bisexual men, people who have had sex with an HIV-positive partner, people who have shared needles and sex workers, among othersshould get tested more often.

The CDC recommends testing once a year for people engaging in these higher-risk behaviors. Forsexually active gay and bisexual men, the CDC says testing every three to six months is beneficial.

If you are pregnant, and even if you are in a monogamous relationship, the CDC recommends testing to be sure and to reduce the risk of transmitting HIV to your child or partner. The sooner a pregnant woman starts treatment, the less likely she is to transmit HIV to her child.

Most HIV tests involve blood or oral fluid. Clinics, hospitals, community health centers and many other locations provide HIV testing. Home testing equipment is also available.

HIV does not always show up right away in a test. Your body and the test type determinehow long HIV can take to be detected. Here's a useful guide from theSan Francisco AIDS Foundation on testing windows.

For more information on local testing sites,call1-800-CDC-INFO (1-800-232-4636) or

visitgettested.cdc.gov.

The red ribbon was created in 1991 by artists in New York workingto increase awareness of HIV/AIDS. The artists saw the red ribbon as an easy-to-copy way to show compassion for those living with HIV, given the stigma surrounding it.

"They chose red for its boldness, and for its symbolic associations with passion, the heart and love," according toWorld AIDS Day organizers.

Contributing: Jordan Culver, USA TODAY

Read or Share this story: https://www.usatoday.com/story/news/health/2019/12/01/world-aids-day-2019-faqs-hiv-aids-us-worldwide/4349040002/

Continued here:
World AIDS Day 2019: 37.9M people worldwide were living with HIV at the end of 2018 - USA TODAY

Volumetric Bioprinting: The New Paradigm in Regenerative Medicine – Advanced Science News

Share

Share

Email

Creating an object from a scratch: not just an illusion, but a reality. Nowadays, there is a way to turn your ideas into three-dimensional objects and here, the magic word is 3D printing.

This technique, also called additive manufacturing, consistsofn successive layer-by-layer depositions of material which, all together, form the desired object. Contrary to conventional techniques, 3D printing allows the manufacturing of complex shapes using a small amount of material and reduced number of fabrication steps.

With the term 3D printing, we usually refer to technologies which use polymers, resins and molten metals as printing material to produce three-dimensional objects. However, over the last 30 years, this concept has developed toward new horizons, leading to the production of 3D artificial bio tissues which resemble the architecture and function of native ones. In this case, when used to deposit living cells layer-by-layer, we talk more specifically about 3D bioprinting.

Nowadays, the most common technologies for 3D bioprinting are based on approaches such as extrusion printing, stereolithography, laser-based methods, and melt electrowriting. These technologies have the ability to accurately control the spatial orchestration of multiple cell types and biomaterials in an automated patterning process. However, they also present some disadvantages, e.g., the difficulties in reproducing convoluted geometries, which in fact are typical of native tissues. Moreover, a severe restriction is represented by long printing times when large, physiological-sized constructs need to be fabricated. This characteristic also affects the large-scale production of artificial tissues, thus limiting the adoption of 3D bioprinting at an industrial level.

In order to overcome these limitations, Prof. Riccardo Levato of the University Medical Center Utrecht, the Netherlands, and Prof. Christophe Moser of cole Polytechnique Fdral Lausanne (EPFL), Switzerland, have proposed a new strategy for the 3D bioprinting. In their recently published article they present a Volumetric Bioprinting (VBP) approach to create any convoluted free-form geometry with unprecedented speed of fabrication.

This method takes inspiration from the principle of computed tomographycommonly used in medical imagingalthough in reverse. In VBP, a cell-friendly visible laser light is used to cast multiple tomographic projections onto a light-sensitive hydrogel embedding stem cells.Although the whole volume is photo-exposed, the composition of these projections creates a 3D light field that provides enough energy to crosslink the hydrogel only in correspondence to the desired design. This results in a 3D construct, floating in the host hydrogel, which can be realized in the time frame of a few tens of seconds.

Contrary to other bioprinting technologies, e.g., stereolithography, which works in the time scale of hours to produce clinically-relevant sized (> cm3) structures, VBP thus permits the fabrication of living tissue constructs with analogous dimensions and complex 3D architectures by strongly reducing the fabrication times. As a consequence, VBP not only leads to high mimicry of the architecture of human tissues, but it preserves cells by minimizing the time outside of their optimal culture environment.

Given the freedom to print any complex geometry, anatomical, patient-specific grafts with unprecedented precision and short fabrications times, VBP lends itself to be the new paradigm of regenerative medicine, also paving the way for the scaling-up of tissue production. Thanks to these characteristics, Prof. Levato and Prof. Moser expect this approach will find application in many fields also outside tissue engineering, even including soft robotics. As they claimed, We expect Volumetric Bioprinting technology to be part of the bioprinting toolkit that will one day create fully functional organs.

In the future, the authors aim to further improve VBP technology by addressing the structural function of load bearing tissues, developing new materials and fully matching the function between their biofabricated tissues and the native ones. This sounds promising to us: we are looking forward to seeing new developments!

More here:
Volumetric Bioprinting: The New Paradigm in Regenerative Medicine - Advanced Science News

Heres what you might have missed from the week in business – The Boston Globe

PRIYANKA DAYAL MCCLUSKEY

A group of leading Boston-area universities, hospitals, and corporations will create a new center for bio-manufacturing and innovation in or near the city, Harvard University said Monday, and hopes to have the facility up and running by 2022 or even 2021 in an effort to protect the areas leadership in the life sciences. That leadership is threatened by severe bottlenecks in bio-manufacturing, said Harvard officials, who spent two years canvassing experts on what Massachusetts needs to do to keep promoting biotech in both academia and industry. Bio-manufacturing refers to growing vast quantities of human cells, including genetically engineered ones and those produced from stem cells; strands of genetic material that can be used to treat diseases; and other biological molecules. A bio-manufacturing facility opened at Dana-Farber Cancer Institute in 2018, but the $35 million, 30,000-square-foot cell-manufacturing space became oversubscribed almost immediately. Dana-Farber is among the initial partners in the planned facility, for which the organizers have $50 million in commitments to cover design, construction, and early operation. The others include, besides Harvard, the Massachusetts Institute of Technology, Fujifilm Diosynth Biotechnologies, GE Healthcare Life Science, Alexandria Real Estate Equities, Beth Israel Deaconess Medical Center, Boston Childrens Hospital, Brigham and Womens Hospital, and Massachusetts General Hospital.

SHARON BEGLEY, STAT

One of the business pioneers of the Seaport District appears ready to grow in a new corner of the burgeoning neighborhood. Vertex Pharmaceuticals is poised to lease a building under construction in the Raymond L. Flynn Marine Industrial Park, the biotechnology company said this week. A lease has not been finalized, but Vertex and development firm Related Beal are in advanced talks for 256,000 square feet of space at Innovation Square, a lab and office project Related is building on Tide Street. Vertex would use it as a research and manufacturing facility for genetic and cellular therapies, a key part of the companys push into treatments for diseases beyond cystic fibrosis, which has long been its main focus. Earlier this year, the drug maker bought Watertown-based Exonics, which is developing gene therapies for Duchenne muscular dystrophy, and Semma Therapeutics, which is working on medicines for type 1 diabetes. Vertex also is moving forward in clinical trials of gene editing treatments.

TIM LOGAN

The company that owns the A.C. Moore chain of arts supply stores is leaving the industry and is planning to shut down all of its estimated 145 stores, which includes 12 in Eastern Massachusetts and on Cape Cod. At the same time that Nicole Crafts announced its departure plans, it also said the operator of the Michaels chain of arts and crafts stores will assume the leases in as many as 40 current A.C. Moore locations. The companies did not immediately lay out a timetable for the A.C. Moore closures, nor did Michaels identify the stores it will be taking over, remodeling, and then reopening next year. Nicole Crafts chief executive Anthony Piperno said in a statement that the stores will remain open for the time being, but the company will no longer accept online orders as of Monday.

JOHN R. ELLEMENT

The path is now clear for mobile sports betting to begin in New Hampshire in January. The New Hampshire Executive Council approved a contract on Monday between Boston-based DraftKings and the New Hampshire Lottery. A deal in the future with another sports betting operator such as FanDuel is not out of the question, but DraftKings emerged as the winner of a competitive bidding process in which New Hampshire preferred DraftKings app, implementation timeline, and the 51 percent gaming revenues it will hand over to the state. In the spring, municipalities will decide whether or not to open physical sports books in their towns. New Hampshire sports bettors will have to be 18 years or older, and they will not be permitted to bet on New Hampshire college teams or on any college games being played in New Hampshire. DraftKings will open an office in the Granite State.

MICHAEL SILVERMAN

For Belmont-raised Margaret Low, its a doubly sweet homecoming. WBUR-FM said Monday that the former NPR executive, who most recently ran The Atlantics events business, would take over in mid-January as its CEO and general manager. Its a high-profile hire for the Boston radio station after a period of turmoil. Low, 61, has spent much of her career in Washington, D.C. Now she is returning to the region she moved away from shortly after college, and to the public radio world she left in 2014 after a 25-year stint with NPR. WBUR said that Lows extensive news skills combined with business success at The Atlantic magazines events division made her the ideal choice to lead the station as it confronts challenges in the fast-moving media industry. Low also will have to manage the stations sometimes contentious relationship with Boston University, which owns WBURs broadcast license and whose decisions have at times frustrated management and staff. Her hiring comes eight months after WBUR parted ways with general manager Charlie Kravetz, who significantly expanded the station during his eight years at the helm, including its move into podcasting and the opening of CitySpace, its local programming venue. Kravetz was highly regarded but took a hit for his handling of Tom Ashbrook, who was forced out as host of the nationally syndicated show On Point after a review found he had created a hostile work environment. Kravetzs departure followed a February vote by about 100 workers to unionize amid complaints about the work environment.

LARRY EDELMAN

Continued here:
Heres what you might have missed from the week in business - The Boston Globe

Phase 2 Trial Data on ALS NurOwn Therapy, Supporting Safety And Early Efficacy, Published – ALS News Today

NurOwn showed a good safety profile, as well as potential efficacy in a Phase 2 clinical trial that included people with rapidly progressing amyotrophic lateral sclerosis (ALS).

Trial results, which have been previously reported, have now been published in the journalNeurology in a paper titled, NurOwn, phase 2, randomized, clinical trial in patients with ALS.

NurOwn, which is being developed by BrainStorm Cell Therapeutics, is a stem cell-based therapy. It involves taking mesenchymal stem cells (MSCs), a type of cell capable of differentiating into other cell types, from a person.

These MSCs are modified so they produce more neurotrophic factors (NTFs) compounds that help drive the growth and survival of nervous tissue. The cells are then re-introduced to the body by injection into muscles and/or the spinal canal (termed intramuscular and intrathecal injection, respectively).

In the Phase 2 trial (NCT02017912), which was funded by BrainStorm, 48 people with ALS were enrolled; 36 were treated with NurOwn, and 12 were given a placebo. Participants received the treatment after a three-month pretransplant period, and were followed for six months after treatment.

The participants were predominantly (72.9%) male, and their average age was 51.1 years.

The studys primary goal of the study was to evaluate safety, measured by number of patients with adverse events to treatment, and this goal was met. The use of NurOwn was found to be safe and well-tolerated.

Eleven participants nine in the treatment group and two in the placebo group developed 16 serious adverse events (SAEs).

All treatment-emergent SAEs [those that occurred after start of treatment] were deemed to be related to ALS disease progression, and none was considered possibly, probably, or definitely related to study treatment, the researchers noted.

Data were also analyzed for early indications of treatment efficacy. Researchers specifically looked at rate of disease progression, as measured by the slope (that is, the change over time) in scores on the Revised ALS Functional Rating Scale (ALSFRS-R).

Overall, these rates were not significantly different between the NurOwn-treated and placebo groups.

However, in a subset of 21 patients with particularly rapid disease progression (15 given NurOwn and six a placebo), the average rate of disease progression showed a significantly improvement at two weeks (+3.3 vs. 1.3) and four weeks (+2.0 vs. 0.1) following treatment for those that got NurOwn.

Rapid progressors were defined in this study, at enrollment, as those with a decline of more than 2 points in ALSFRS-R scores during the pretreatment period.

This positive trend continued for all study time points, but it was not statistically significant after four weeks.

The researchers also looked at the proportion of patients with an improvement of at least 1.5 points each month, based on the reasoning that, responder analyses may more accurately capture individual treatment responses than changes in mean slope alone. That is, because each individual with ALS is different, some might be more likely to respond to treatment than others.

At four weeks post-treatment, a significantly greater proportion of those given NurOwn compared to placebo met this responder threshold (47% vs. 9%). In the rapid progression group, there were significant differences at both week four and week twelve (80% vs. 0%, and 53% vs. 0%, respectively).

For all of the above efficacy measurements, the greatest response was seen shortly following the injection, with decreasing response over time. This may suggest the need for repeated treatments to maintain a sustained therapeutic effect, the researchers wrote.

Cerebrospinal fluid (CSF) was collected just before and two weeks after the injection. Analysis of this fluid, broadly, showed an increase in levels of NTFs and a decrease in inflammatory markers, which suggests that NurOwn works as intended. (CSFfluid surrounds the brain and spinal cord.)

Specifically, the levels of monocyte chemoattractant protein-1 (MCP-1), a marker of immune cell infiltration and neuroinflammation, were significantly lower post-treatment in patients given NurOwn, while no significant change was observed in the placebo group. This correlated with ALSFRS-R slope improvement at all time points.

[W]e observed a clear biological effect of the treatment on CSF biomarkers to support its proposed mechanism of action in ALS, Robert H. Brown Jr., PhD, MD, of the University of Massachusetts Medical School and a study co-author, said in a BrainStorm press release.

We met our primary endpoint and demonstrated that a single dose of NurOwn was safe and well-tolerated while supporting NurOwns mechanism of action on neuroprotection and neuroinflammation pathways in ALS, added Ralph Kern, MD, MHSc, chief operating officer and chief medical officer of BrainStorm.

We look forward to completing the current Phase 3 study to confirm the promising Phase 2 findings and expand our understanding of the potential of MSC-NTF cell therapy in ALS, Kern added.

A fully enrolled, placebo-controlled Phase 3 study (NCT03280056) is underway in the U.S. in 200 ALS patients, and a secondary safety analysis found no new concerns. The trial is expected to conclude in late 2020, with results announced shortly thereafter.

Results from the [Phase 2] study underscore the importance of conducting a larger Phase 3 clinical trial that will build upon the data collected in our Phase 2 study, said Chaim Lebovits, Brainstorms president and chief executive officer. We look forward to reporting our clinical results in the scientific literature and through corporate announcements.

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

Total Posts: 279

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Tcnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

See the original post here:
Phase 2 Trial Data on ALS NurOwn Therapy, Supporting Safety And Early Efficacy, Published - ALS News Today

Harnessing Gamma T Cells To Bring Effective Therapies to Patients – Technology Networks

GammaDelta Therapeutics is a company that focusses on utilizing the unique properties of gamma delta () T cells to develop novel immunotherapies for patients.Through their research, the companys scientists have discovered a number of targets and antibodies that have the potential to modulate the activity of T-cells in situ. Therefore, GammaDelta Therapeutics recently announced the formation of Adaptate Biotherapeutics, a spin-out company that will focus on research in this area.

Technology Networks spoke with Natalie Mount, CEO of Adaptate BioTherapeutics, to learn more about the company's aims and the challenges faced when developing immunotherapies and advancing them into clinical studies.

Molly Campbell (MC) Please can you tell us more about T-cell based cell therapy products and their potential applications?Natalie Mount (NM): T cells play an increasingly appreciated critical role in immune surveillance, being able to recognize malignant/transformed cells through a pattern of stress markers. The recognition mechanism is not major histocompatibility complex (MHC) restricted and not dependent on a single antigen.

T cells therefore have potential in a range of disease indications, including both hematological and solid malignancies and a positive correlation between T cell infiltration and prognosis/survival in patients has been determined in a range of oncology indications in studies published in the literature by other groups. Additionally, as a cell therapy, T cells can be used in an allogeneic setting (ie, T cells can be used for unrelated recipients without a requirement for matching).

Both Adaptate Biotherapeutics and GammaDelta Therapeutics are focussed on harnessing the potential of T cells, in particular the V1 subtype which is the predominant T cell type in tissue.This is based on data originating from the labs of Professor Adrian Hayday of Kings College London and the Crick Institute, supported by Cancer Research Technology and also from Professor Bruno Silva Santos of Institute for Molecular Medicine at the University of Lisbon, Portugal.

Previous clinical trials conducted by other groups/companies targeting or using T cells in cancer have focussed on the V2 subtype which is predominant in the blood. These trials have demonstrated safety, but efficacy has been limited.Compared to V2 cells, V1 cells, which are the focus of work at Adaptate Biotherapeutics and GammaDelta Therapeutics, are less susceptible to exhaustion and activation induced cell death. Expansion of donor derived V1 has been shown to be a positive prognostic indicator for acute myeloid leukemia patients following hematopoietic stem cell transplant.

MC: Why are current immunotherapy treatment approaches limited?NM: Immunotherapy approaches have had very significant success and impact in Oncology recently, however, challenges and unmet needs remain.One challenge is effective treatment of solid tumors. The hypoxic, low nutrient tumor environment provides a challenge for successful infiltration and activation of T cells. However, V1 T cells have real potential as they are naturally tissue resident and hence primed for this environment. In addition, their ability to recognize malignant cells by a pattern of markers expressed by dysregulated, transformed cells rather than one specific antigen presented by the MHC provides an additional advantage for both specificity of response and maintenance of efficacy.

T cells act as orchestrators of an immune response and, following recognition of a cell as malignant, they induce maturation of monocytes and signal to alpha beta T cells, hence increasing immunogenicity of the tumor and providing a sustained response, with potential even in tumors with low mutational load which have proven challenging with other immunotherapies.

MC: The new spin-out company, Adaptate Biotherapeutics, will build on GammaDelta's knowledge to modulate T-cell activity using therapeutic antibodies. Why have you decided to create a spin-out focusing on this area of research?NM: GammaDelta Therapeutics was formed in 2016 to harness the unique properties of T cells, and since then has gained extensive knowledge of T-cell biology. In addition to gaining insight into cell growth and isolation, the companys scientists have also discovered a number of targets and antibodies that have potential to modulate the activity of T-cells in situ.

GammaDelta Therapeutics now has a pipeline of cell therapy products progressing into clinical development under the guidance of CEO, Dr Paolo Paoletti.

Adaptate Biotherapeutics will be developing antibodies which will be administered to cancer patients to modulate activity of the patient's gamma delta T cells in situ.

Delivery of cell therapy and antibody therapeutics each needs focus and specific skillsets and formation of two independent entities will facilitate this. The two companies share a common goal to harness the potential of T cells to bring effective therapies to patients. Both benefit from support of the scientific founding team and have common investors, Abingworth and Takeda Pharmaceuticals.MC; Your goal is to develop targets and antibodies that can modulate the activity of T-cells and advance them into clinical studies. What challenges exist here, and how do you hope to overcome them?

Our assets at Adaptate Biotherapeutics are currently at the pre-clinical stage and therefore face the non-clinical development risks for a novel therapy. However, these risks are mitigated by biology understanding from our scientific founders and the work at GammaDelta Therapeutics to date.

One of our challenges is in selecting the most suitable patient population for initial trials. There is potential for opportunity for our therapeutics in multiple indications but the utility of animal models in modelling the human immune compartment and human tumor setting is limited. Therefore in vitro and ex vivo models are important, in addition to the learnings from other clinical studies.

MC: GammaDelta Therapeutics formed in 2016 to gain extensive knowledge of T-cell biology and to developing a portfolio of investigational cell therapies. Some of these cell therapies are poised to enter clinical development. Can you tell us any further information about these therapies?NM: GammaDelta was set up to develop cell-based therapy utilizing ex-vivo expanded tissue resident gd T cells. Subsequent acquisition of Lymphact SAS allowed GammaDelta to augment its capabilities with a platform for ex-vivo expansion of blood derived V1 cells. GammaDelta is focussed on progressing ex-vivo expanded skin and blood derived V1 cells to the clinic both in unengineered and engineered formats. Clinical trials are currently on track to commence in the next 12-18 months.

MC: Your press release states: "The two companies will continue sharing their insights into T-cell biology as they work towards developing different therapeutic modalities". How will you continue to share insights here?NM: Antibodies and cells represent complementary approaches to realizing the potential of T cell activity for patients with solid and haematological malignancies.

The two companies will work together in areas of common interest in the biology of these fascinating cells, such as understanding the phenotype and behavior of T cells in tumors and mechanisms of cell regulation as well as the effects of antibody on the T cells.

We have deliberately established a contractual framework that allows efficient collaboration between scientists of both the companies via formal and informal meetings.

MC: What are your hopes for the future of Adaptate Biotherapeutics?NM: This is a remarkable time in the development of new immune therapies, and the role of "non-conventional" cell types of the immune system is coming to the fore as we recognize the successes achieved to date and the needs of patients and related scientific challenges that remain.

Both GammaDelta Therapeutics and Adaptate Biotherapeutics are at the lead of translating our increasing understanding of T cell biology and its potential into therapies to address these unmet needs.

Adaptate Biotherapeutics has a fantastic opportunity to build and accelerate a portfolio of antibody-based approaches in this novel area and I look forward to the successful translation of this science into therapies with the support of our investors at Abingworth and Takeda Pharmaceuticals.

Dr Natalie Mount, CEO of Adaptate Biotherapeutics was speaking with Molly Campbell, Science Writer, Technology Networks.

See the article here:
Harnessing Gamma T Cells To Bring Effective Therapies to Patients - Technology Networks